New drug could shield preemie lungs from chronic disease
NCT ID NCT05898633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called rfhSP-D in 18 premature babies born before 30 weeks. The goal was to find the safest dose that might prevent chronic lung disease, a common complication in preemies. The drug was given along with standard care to babies on breathing machines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant surfactant protein D (rfhSP-D)
- What this could lead to
- If successful, this could lead to a new treatment to prevent chronic lung disease in premature infants, reducing lifelong breathing problems.
- What could go wrong
- This is a very early Phase 1 trial with only 18 babies, focused on safety. The drug may not work or could have side effects. Much more research is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University College London Hospitals
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Mother's Omega-3 supplement shield preterm Babies' lungs?
- A new MRI test could spot a hidden Heart-Lung danger in babies
- Early therapy may rewire motor development in premature infants
- Can scans and scope tests unlock better care for tiny lungs?
- Which inhaler works best for preterm children with lung disease? a study seeks answers
- Human milk mouth care may shield preemies from lung infections